All In Biotech

Drug Trial Radar · NCT07916961

Study of AB-110 in Healthy and Hypertensive Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-110 in Healthy and Hypertensive Participants

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Antlia Bioscience, IncIndustry
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI \> 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety. The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety, the study is designed to enable insights on secondary and exploratory research questions, including Blood Pressure (BP) reduction and exploratory biomarkers.

Conditions

  • Hypertension (HTN)
  • Healthy Adult Participants

Interventions

  • Active drugDrug

    AB-110 will be administered by subcutaneous (SC) injection

  • AB-110 Matching PlaceboDrug

    Placebo doses will be administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events and Serious Adverse Events, overall, by severity and relationship to AB-110/placeboTime frame: Part A: From baseline up to Day 21; Part B: From baseline up to Day 36
  2. Incidence of injection site reactionsTime frame: Part A: From baseline up to Day 21; Part B: From baseline up to Day 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.